Please assess the completion status of the following clinical trial:

Trial Title: This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically or cytologically confirmed recurrent or metastatic HPV associated tumor (cervical, oropharyngeal, vulvar, vaginal, anal, or penile) with documented disease progression.~* Arm 1, Phase 1 dose escalation: Cervical, HPV+ oropharyngeal, vulvar, vaginal, anal, or penile~* Arm 1, Cohort A: Cervical cancer~* Arm 1, Cohort B: HPV+ Oropharyngeal cancer~* Arm 2 Phase 1 dose escalation and Cohort C: Cervical, oropharyngeal, vulvar, vaginal, anal, or penile~* Failed, refused or intolerant to systemic therapy~* Measurable disease based on RECIST 1.1~* At least one tumor mass amenable to core needle biopsy~* Arm 2 only: At least one tumor judged as being safely injectable~* ECOG performance status 0 or 1~* Demonstrate adequate organ function~* Additional Inclusion criteria exist~Key Exclusion Criteria:~* Prior systemic therapy within 4 weeks.~* Patients receiving prior XRT must have recovered from any acute toxicity.~* Currently receiving/received experimental therapy within 4 weeks.~* Prior treatment with any HPV vaccine therapy for cancer.~* Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies or intra-tumoral injections.~* Known active CNS metastases and/or carcinomatous meningitis.~* Clinically significant tumor invasion/ rapidly accumulating ascites, pericardial or pleural effusions.~* Active infection requiring systemic therapy.~* Active autoimmune disease that has required systemic therapy in the past 2 years.~* Conditions likely to have resulted in splenic dysfunction.~* Known HIV/AIDS, active HBV or HCV infection.~* Received prior treatment with vesicular stomatitis (VSV) viral vector.~* Received immunosuppressive medication within 4 weeks. (\>10mg/day prednisone)~* ≥ Grade 2 dyspnea and/or require supplemental oxygen~* Known intolerance to anti-PD-1 or anti-PD-L1 antibody therapy~* Additional Exclusion criteria exist~Exclusion Criteria Household Contacts:~* Patients with household contacts meeting any of the following criteria are ineligible for study entry unless alternate living arrangements can be made, while under contact precautions.~* Women who are pregnant or nursing an infant~* Children \< 1 year old~* Individuals who are severely immunocompromised~* Contact precautions are from initial treatment with MG1-E6E7 to 7 days after the last dose of MG1-E6E7

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Intravenous dosing) (Type: EXPERIMENTAL): Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43.
- Arm 2 (Intravenous and Intra-tumoral injection dosing) (Type: EXPERIMENTAL): Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 \& 29.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43.

Based on this trial design, predict the completion outcome and termination type (if applicable).